Last reviewed · How we verify
capecitabine, oxaliplatin, irinotecan and bevacizumab
capecitabine, oxaliplatin, irinotecan and bevacizumab is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. It is currently in Phase 2 development.
At a glance
| Generic name | capecitabine, oxaliplatin, irinotecan and bevacizumab |
|---|---|
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (PHASE2)
- ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases (PHASE2)
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation (PHASE2)
- GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- capecitabine, oxaliplatin, irinotecan and bevacizumab CI brief — competitive landscape report
- capecitabine, oxaliplatin, irinotecan and bevacizumab updates RSS · CI watch RSS
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI
Frequently asked questions about capecitabine, oxaliplatin, irinotecan and bevacizumab
What is capecitabine, oxaliplatin, irinotecan and bevacizumab?
capecitabine, oxaliplatin, irinotecan and bevacizumab is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Who makes capecitabine, oxaliplatin, irinotecan and bevacizumab?
capecitabine, oxaliplatin, irinotecan and bevacizumab is developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (see full Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline at /company/fondazione-irccs-istituto-nazionale-dei-tumori-milano).
What development phase is capecitabine, oxaliplatin, irinotecan and bevacizumab in?
capecitabine, oxaliplatin, irinotecan and bevacizumab is in Phase 2.